Predictive factors for mortality among non-HIV-infected patients with pulmonary tuberculosis and respiratory failure

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 3, 2009, Pages 335-340

  Lin, S M ^a   Wang, T Y ^a,b   Liu, W T ^a   Chang, C C ^a   Lin, H C ^a   Liu, C Y ^a   Wang, C H ^a   Huang, C D ^a,b   Lee, K Y ^a   Kuo, Han Pin ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b SAINT PAUL S HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Mycobacterium tuberculosis; Nosocomial infection; Pneumonia

Indexed keywords

CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CONFIDENCE INTERVAL; FATALITY; FEMALE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PNEUMONIA; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RESPIRATORY FAILURE; STATISTICAL SIGNIFICANCE; SURVIVOR; TAIWAN; THERAPY DELAY; THORAX RADIOGRAPHY; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; AGED, 80 AND OVER; APACHE; CROSS INFECTION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 62349133063     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367: 938-940.
2. Bureau for Chronic Disease Control. Tuberculosis annual report (Taiwan) 2001. Taipei, Taiwan: Bureau for Chronic Disease Control, 2002.
3. Frame R N, Johnson M C, Eichenhorn M S, et al. Active tuberculosis in the medical intensive care unit: a 15-year retrospective analysis. Crit Care Med 1987; 15: 1012-1014.
4. Erbes R, Oettel K, Raffenberg M, et al. Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J 2006; 27: 1223-1228.
5. Lee P L, Jerng J S, Chang Y L, et al. Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J 2003; 22: 141-147.
6. Levy H, Kallenbach J M, Feldman C, et al. Acute respiratory failure in active tuberculosis. Crit Care Med 1987; 15: 221-225.
7. Penner C, Roberts D, Kunimoto D, et al. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med 1995; 151: 867-872.
8. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of non-invasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585-1591.
9. Zahar J R, Azoulay E, Klement E, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med 2001; 27: 513-520.
10. Agarwal M K, Muthuswamy P P, Banner A S, et al. Respiratory failure in pulmonary tuberculosis. Chest 1977; 72: 605-609.
11. May M T, Sterne J A, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368: 451-458.
12. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274: 968-974.
13. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
14. Simon G. Radiology in epidemiological studies and some therapeutic trials. BMJ 1966; 2: 491-494.
15. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228.
16. Luna C M, Aruj P, Niederman M S, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27: 158-164.
17. Kollef M H, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
18. Lin S M, Huang C D, Lin H C, et al. A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 2006; 26: 551-557.
19. Bass J B Jr, Farer L S, Hopewell P C, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
20. Knaus W A, Draper E A, Wagner D P, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
21. Rao V K, Iademarco E P, Fraser V J, et al. The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 1998; 114: 1244-1252.
22. Rivera-Marrero C A, Stewart J, Shafer W M, et al. The down-regulation of cathepsin G in THP-1 monocytes after infection with Mycobacterium tuberculosis is associated with increased intracellular survival of bacilli. Infect Immun 2004; 72: 5712-5721.
23. Bangalore N, Travis J, Onunka V C, et al. Identification of the primary antimicrobial domains in human neutrophil cathepsin G. J Biol Chem 1990; 265: 13584-13588.
24. Shafer W M, Shepherd M E, Boltin B, et al. Synthetic peptides of human lysosomal cathepsin G with potent antipseudomonal activity. Infect Immun 1993; 61: 1900-1908.
25. Wang J Y, Hsueh P R, Jan I S, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.